Pharmacometric Consultant
qPharmetra, LLC, Netherlands
Max joined qPharmetra in October 2019. His contributions include population PK and PKPD analyses supporting dose selection decisions, and optimizing pediatric study designs, to labeling in target populations.
Prior to joining qPharmetra, Max worked as a Project Pharmacometrician (2017-2019) at Boehringer Ingelheim (Biberach an der Riß, Germany), where he was a core member of multiple early clinical development teams (late pre-clinical – PhI/II) in the therapeutic area Oncology, providing strategic and hands-on pharmacometric modeling and simulation support. Responsibilities included first-in-human dose predictions, informing dose-escalation strategies, tumor progression modeling and interactions with the FDA and its German counterpart, PEI, regarding PK/PD modeling and simulation sections of regulatory submission documents.
Max completed his PhD in Biopharmaceutical Sciences in 2015, Thesis title: “Stress-induced immunomodulation of the innate immune system in cardiovascular disease” investigating the interplay between the innate immune system and acute cardiovascular complications of atherosclerosis in various pre-clinical disease models. After his PhD he worked as a post-doc (2016-2017) in the pharmacology group at the Leiden Academic Centre for Drug Research (LACDR) in collaboration with a biotechnology company, applying pharmacometric (PK and Item Response Theory disease progression) models to support the drug development of their lead compound aimed at slowing down disease progression in patients with Amyotrophic Lateral Sclerosis.